Stock prices for embryonic stem cell research companies took a hit when the U.S. Senate failed to pass a bill to overturn President Bush’s stem cell funding policy by a veto proof margin. Worcester, MA’s, Advanced Cell Technology—which opened an office in California to try and take advantage of the cornicopia of Proposition 71 money—lost value, as did California’s Geron. Some adult stem cell companies also lost ground, but others gained.
Well, the market doesn’t lie: A big part of the drive to overturn Bush’s policy is pure corporate welfare pork. Sooweeee!
Lift My Chin, Lord
Lift my chin, Lord,Say to me,“You are not whoYou feared to be,Not Hecate, quite,With howling sound,Torch held…
Letters
Two delightful essays in the March issue, by Nikolas Prassas (“Large Language Poetry,” March 2025) and Gary…
Spring Twilight After Penance
Let’s say you’ve just comeFrom confession. Late sunPours through the budding treesThat mark the brown creek washing Itself…